Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Oncolgy Times and Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncolgy Times and Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Oncology Times Broadcast News with the Audio Journal of Oncology - January 2009

26:57
 
Share
 

Manage episode 153458763 series 1090654
Content provided by Oncolgy Times and Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncolgy Times and Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Oncology Times Broadcast News January 9th, 2009 American Society of Hematology 2008 Meeting Report Reporting From the 2008 Annual Meeting of the American Society of Hematology, San Francisco The exciting recent ASH conference reflected the vibrant mood of an America boldly tackling economic and political turmoil with post-presidential-election optimism. Peter Goodwin and George Canellos reflect on some of the big stories and talk with key investigators in San Francisco. Francesco Zaja recounts how rituximab has proved effective for treating immune thrombocytopenic purpura (ITP); Hannes Wandt presents compelling data suggesting that platelet transfusions can be withheld in many patients receiving stem cell transplants for their hematologic malignancies; and both Michael Hallek and Tadeusz Robak announce Phase III study findings of improved benefits for patients whose chronic lymphocytic leukemia has been treated by adding rituximab to standard chemotherapy. The ASH President, Kenneth Kaushansky, plus Linda Burns and George Canellos contribute their comments to put the new findings into clinical perspective for the busy oncologist.
  continue reading

19 episodes

Artwork
iconShare
 
Manage episode 153458763 series 1090654
Content provided by Oncolgy Times and Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncolgy Times and Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Oncology Times Broadcast News January 9th, 2009 American Society of Hematology 2008 Meeting Report Reporting From the 2008 Annual Meeting of the American Society of Hematology, San Francisco The exciting recent ASH conference reflected the vibrant mood of an America boldly tackling economic and political turmoil with post-presidential-election optimism. Peter Goodwin and George Canellos reflect on some of the big stories and talk with key investigators in San Francisco. Francesco Zaja recounts how rituximab has proved effective for treating immune thrombocytopenic purpura (ITP); Hannes Wandt presents compelling data suggesting that platelet transfusions can be withheld in many patients receiving stem cell transplants for their hematologic malignancies; and both Michael Hallek and Tadeusz Robak announce Phase III study findings of improved benefits for patients whose chronic lymphocytic leukemia has been treated by adding rituximab to standard chemotherapy. The ASH President, Kenneth Kaushansky, plus Linda Burns and George Canellos contribute their comments to put the new findings into clinical perspective for the busy oncologist.
  continue reading

19 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play